Cargando…

Identifying Early Predictive Markers for Immune-Related Adverse Events in Nivolumab-Treated Patients with Renal Cell Carcinoma and Gastric Cancer

BACKGROUND: Neutrophil-to-lymphocyte (NLR) and platelet-to-lymphocyte (PLR) ratios can indicate poor disease prognosis and are inflammation markers. We investigated the role of NLR and PLR as effective predictive markers of immune-related adverse event (irAE) onset in patients treated with nivolumab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takada, Shinya, Murooka, Hidetaka, Tahatsu, Kanae, Yanase, Maki, Umehara, Kengo, Hashishita, Hirokazu, Toru, Harabayashi, Satoru, Maruyama, Sagawa, Tamotsu, Fujikawa, Koshi, Sato, Hideki, Kozo, Mino
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	West Asia Organization for Cancer Prevention 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272606/ https://www.ncbi.nlm.nih.gov/pubmed/35225483 http://dx.doi.org/10.31557/APJCP.2022.23.2.695

Ejemplares similares

Skin Disorders and Primary Tumor Location as Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated with Cetuximab and Chemotherapy
por: Takada, Shinya, et al.
Publicado: (2018)

Clinical Management of Potential Toxicity of Abemaciclib and Approaches to Ensure Treatment Continuation
por: Takada, Shinya, et al.
Publicado: (2023)

Predictors of the Onset of Type 1 Diabetes Obtained from Real-World Data Analysis in Cancer Patients Treated with Immune Checkpoint Inhibitors
por: Takada, Shinya, et al.
Publicado: (2020)

Association between Area under the Curve Estimated from Carboplatin Dose and Incidence of Severe Thrombocytopenia in Patients with Non-Hodgkin’s Lymphoma on DeVIC Therapy
por: Umehara, Kengo, et al.
Publicado: (2023)

Analgesic effects of indomethacin spray on drug‐induced oral mucositis pain in patients with cancer: A single‐arm cross‐sectional study
por: Hata, Hironobu, et al.
Publicado: (2021)

Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane
por: Satake, Hironaga, et al.
Publicado: (2018)

Effect of Systemic Corticosteroid Therapy on the Efficacy and Safety of Nivolumab in the Treatment of Non-Small-Cell Lung Cancer
por: Umehara, Kengo, et al.
Publicado: (2021)

Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study
por: Saka, Hideo, et al.
Publicado: (2017)

Progression patterns and site‐specific responses in advanced gastric cancer patients treated with nivolumab
por: Kadono, Toru, et al.
Publicado: (2023)

Hilar/mediastinal and cutaneous drug-induced sarcoidosis-like reaction associated with immune checkpoint inhibitors in metastatic colorectal cancer: a case report
por: Sagawa, Tamotsu, et al.
Publicado: (2023)

Metastases of soft tissue sarcoma to the liver: A Historical Cohort Study from a Hospital‐based Cancer Registry
por: Okamoto, Masanori, et al.
Publicado: (2020)

Comparative study of lymph node dissection, and oncological outcomes of laparoscopic and open radical nephroureterectomy for patients with urothelial carcinoma of the upper urinary tract undergoing regional lymph node dissection
por: Abe, Takashige, et al.
Publicado: (2018)

Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab
por: Sagawa, Tamotsu, et al.
Publicado: (2020)

Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer
por: Aoki, Masahiko, et al.
Publicado: (2019)

Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours
por: Yonemori, Kan, et al.
Publicado: (2016)

Case Report: Longitudinal monitoring of clonal evolution by circulating tumor DNA for resistance to anti-EGFR antibody in a case of metastatic colorectal cancer
por: Sagawa, Tamotsu, et al.
Publicado: (2023)

Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab
por: Masuda, Ken, et al.
Publicado: (2019)

Immune thrombocytopenia induced by nivolumab in a patient with non-small cell lung cancer
por: Mori, Hidenori, et al.
Publicado: (2019)

Diagnostic outcome of ureteroscopy in urothelial carcinoma of the upper urinary tract: Incidence of later cancer detection and its risk factors after the first examination
por: Murahashi, Norihiro, et al.
Publicado: (2015)

Renin-angiotensin system inhibitors may have an advantage over calcium channel blockers in reducing proteinuria in gastric cancer patients receiving ramucirumab
por: Chiba, Takeshi, et al.
Publicado: (2022)

A Case of IgA Vasculitis During Nivolumab Therapy for Renal Cell Carcinoma
por: Nagaoka-Takatori, Asami, et al.
Publicado: (2021)

Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma
por: Han, Nanumi, et al.
Publicado: (2018)

Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: A case report of successful management
por: Yanase, Takahiro, et al.
Publicado: (2020)

Outcome and prognostic factors in metastatic urothelial carcinoma patients receiving second-line chemotherapy: an analysis of real-world clinical practice data in Japan
por: Matsumoto, Ryuji, et al.
Publicado: (2018)

Remission of ulcerative colitis flare-up induced by nivolumab
por: Iwamoto, Maho, et al.
Publicado: (2020)

Relapsed Myasthenia Gravis after Nivolumab Treatment
por: Mitsune, Ayumi, et al.
Publicado: (2018)

Effect of Azithromycin on Mineralized Nodule Formation in MC3T3-E1 Cells
por: Kato, Kengo, et al.
Publicado: (2021)

Self-Propelled Motion Sensitive to the Chemical Structure of Amphiphilic Molecular Layer on an Aqueous Phase
por: Matsuo, Muneyuki, et al.
Publicado: (2021)

STAT3 signal transduction through interleukin-22 in oral squamous cell carcinoma
por: NAHER, LUTFUN, et al.
Publicado: (2012)

Remarkable response of nivolumab‐refractory lung cancer to salvage chemotherapy
por: Ogawara, Daiki, et al.
Publicado: (2017)

Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab
por: Kawashima, Yosuke, et al.
Publicado: (2019)

Successful Treatment of Pulmonary Pleomorphic Carcinoma with Nivolumab: A Case Report
por: Fujimoto, Eriko, et al.
Publicado: (2018)

The impact of nutritional status in nivolumab-treated patients with advanced esophageal cancer
por: Takegawa, Naoki, et al.
Publicado: (2023)

Systemic Sarcoidosis with Thyroid Involvement
por: Okuma, Hideyuki, et al.
Publicado: (2017)

A remarkable response to combination chemotherapy with nivolumab and ipilimumab in a patient with primary pulmonary choriocarcinoma: a case report
por: Iso, Hirokazu, et al.
Publicado: (2023)

Steroid-responsive Nivolumab-induced Involuntary Movement with Anti-thyroid Antibodies
por: Maetani, Yuta, et al.
Publicado: (2019)

Validation of the Japanese version of the Body Image Scale for bladder cancer patients
por: Sato, Miho, et al.
Publicado: (2022)

MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
por: Yoshimura, Katsuhiro, et al.
Publicado: (2021)

The new prognostic score for unresectable or recurrent gastric cancer treated with nivolumab: A multi‐institutional cohort study
por: Sato, Sho, et al.
Publicado: (2021)

Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer
por: Ozaki, Yukinori, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p94qec646vstc56prd043pi384